Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.76+0.01 (+0.15%)
Close on Nov 20, 2026Market cap $362.54MP/E –Yield –
Avalo Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Avalo Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$26.85M. For fiscal 2022 it was -$26.85M. The highest annual figure on record is $12.56M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$26.85M | – |
| FY2021 | Dec 31, 2021 | -$71.01M | – |
| FY2020 | Dec 31, 2020 | -$40.60M | – |
| FY2019 | Dec 31, 2019 | -$19.40M | – |
| FY2018 | Dec 31, 2018 | -$3.69M | -129.4% |
| FY2017 | Dec 31, 2017 | $12.56M | – |
| FY2016 | Dec 31, 2016 | -$14.61M | – |
| FY2015 | Dec 31, 2015 | -$10.18M | – |
| FY2014 | Dec 31, 2014 | -$15.54M | – |
| FY2013 | Dec 31, 2013 | -$11.51M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -$3.94M | – |
| Q3 FY2022 | Sep 30, 2022 | $5.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.93M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.81M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.48M | – |
| Q3 FY2018 | Sep 30, 2018 | -$577.48K | -103.0% |
| Q2 FY2018 | Jun 30, 2018 | -$340.38K | – |
| Q1 FY2018 | Mar 31, 2018 | -$299.65K | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.56M | – |
| Q3 FY2017 | Sep 30, 2017 | $19.12M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.76M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.72M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.44M | – |
See a number that looks wrong?